Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Neoadjuvant Vidutolimod and Nivolumab in High-Risk Resectable Melanoma: A Prospective Phase II Trial

Diwakar Davar,Robert M. Morrison,Amiran K. Dzutsev,Arivarasan Karunamurthy,Joe-Marc Chauvin, Florent Amatore,Julie S. Deutsch,Rodrigo X. Das Neves,Richard R. Rodrigues,John A. McCulloch,Hong Wang,Douglas J. Hartman,Jonathan H. Badger,Miriam R. Fernandes,Yulong Bai,Jie Sun,Alicia M. Cole, Poonam Aggarwal, Jennifer R. Fang,Christopher Deitrick,Riyue Bao,Umamaheswar Duvvuri,Shaum S. Sridharan,Seungwon W. Kim,Haroon A. Choudry,Matthew P. Holtzman,James F. Pingpank, James Patrick O'Toole,Richelle DeBlasio, Yang Jin,Quanquan Ding,Wentao Gao, Christopher Groetsch,Ornella Pagliano,Amy Rose, Corey Urban,Jagjit Singh,Prajan Divarkar,David Mauro,Dmitri Bobilev,James Wooldridge,Arthur M. Krieg,Matthew G. Fury,Jeffrey R. Whiteaker,Lei Zhao,Amanda G. Paulovich,Yana G. Najjar,Jason J. Luke,John M. Kirkwood,Janis M. Taube,Hyun Jung Park,Giorgio Trinchieri,Hassane M. Zarour

CANCER CELL（2024）

Cited 1|Views21
Key words
neoadjuvant,immunotherapy,ICI,PD-1,melanoma,TLR9,vidutolimod,innate agonist,macrophage,pDC
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined